Follow

Submissions from 2024

Link

Combination biologics or targeted synthetic disease-modifying anti-rheumatic drugs in the treatment of spondyloarthritis: a systematic literature review., Rand Abedalweli, Michelle Nguyen, and Atul Deodhar

Link

Improving the nosology of Long COVID: it is not so simple., Leonard H Calabrese and Philip Mease

Link

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study., Laura C Coates, Laure Gossec, Miriam Zimmermann, May Shawi, Emmanouil Rampakakis, Natalie J Shiff, Alexa P Kollmeier, Xie L Xu, Peter Nash, Philip J Mease, and Philip S Helliwell

Link

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study., Laura C Coates, Proton Rahman, Philip J Mease, May Shawi, Emmanouil Rampakakis, Alexa P Kollmeier, Xie L Xu, Soumya D Chakravarty, Iain B McInnes, and Lai-Shan Tam

Link

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update., Laure Gossec, Andreas Kerschbaumer, Ricardo J O Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, Annamaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Philip Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Georg Schett, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée van der Heijde, and Josef S Smolen

Link

Effectiveness of bDMARDs in ankylosing spondylitis patients by biologic use: experience from the CorEvitas PsA/SpA Registry., Philip Mease, Taylor Blachley, William N Malatestinic, Leslie R Harrold, Blessing Dube, Jeffrey R Lisse, Rebecca J Bolce, and Theresa M Hunter

Link

Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis., Philip Mease, Dafna D Gladman, Joseph F Merola, Peter Nash, Stacy Grieve, Victor Laliman-Khara, Damon Willems, Vanessa Taieb, Adam R Prickett, and Laura C Coates

Link

Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis., Philip J Mease, Soumya Reddy, Sarah Ross, Jeffrey R Lisse, Paulo Reis, Kirstin Griffing, Christophe Sapin, Aisha Vadhariya, and Daniel E Furst

Link

Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison., Philip J Mease, Richard B Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, and Iain B McInnes

Link

Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison., Philip J Mease, Richard B Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, and Iain B McInnes

Link

Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Ruizhi Sophia Zhao, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, and Joseph F Merola

Link

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Pamela Young, Lara Fallon, Rajiv Mundayat, Oluwaseyi Dina, Taylor Blachley, Nicole Middaugh, and Alexis Ogdie

Link

Exploring the complexities of pain phenotypes: OMERACT 2023 chronic pain working group workshop., Tim Pickles, Mary Cowern, Robin Christensen, Sabrina M Nielsen, Lee S Simon, Caitlin M P Jones, Lara J Maxwell, Beverley Shea, Vibeke Strand, Zahi Touma, Karine Toupin-April, Philip Mease, and Ernest Choy

Link

Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis., Proton Rahman, Iain B McInnes, Atul Deodhar, Georg Schett, Philip Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, and Dennis McGonagle

Link

Modulation of IL-23 Signaling With Guselkumab in Biologic-Naïve Patients Versus TNF Inhibitor-Inadequate Responders With Active Psoriatic Arthritis., Stefan Siebert, Laura C Coates, Georg Schett, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Philip J Mease, and Atul Deodhar

Link

Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project., Shikha Singla, Andre Ribeiro, Murat Torgutalp, Philip Mease, and Fabian Proft

Link

Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial., Vibeke Strand, Laure Gossec, Laura C Coates, Alexis Ogdie, Jiyoon Choi, Brandon Becker, Joe Zhuo, Thomas Lehman, Miroslawa Nowak, Ayanbola Elegbe, Philip Mease, and Atul Deodhar

Link

Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials., Rui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, Mark Lebwohl, Alice B Gottlieb, Philip Mease, Atul Deodhar, Weibin Bao, Meryl Mendelson, Brian Porter, Deepa Chand, and Victor Dong

Link

Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison., Richard B Warren, Iain B McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, and Philip Mease

Submissions from 2023

Link

Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons., Nurullah Akkoç, Carlos H Arteaga, Simone E Auteri, Marissa Betts, Kyle Fahrbach, Mindy Kim, Sandeep Kiri, Binod Neupane, Karl Gaffney, and Philip J Mease

Link

Patient clusters identified by machine learning from a pooled analysis of the clinical development programme of secukinumab in psoriatic arthritis, ankylosing spondylitis and psoriatic arthritis with axial manifestations., Xenofon Baraliakos, Effie Pournara, Laura C Coates, Philip Mease, Samad S Jahandideh, and Dafna D Gladman

Link

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis., Gerd R Burmester, Stanley B Cohen, Kevin L Winthrop, Peter Nash, Alan D Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P Lacerda, Hannah Palac, Tim Shaw, Philip J Mease, and Emma Guttman-Yassky

Link

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study., Laura C Coates, Philip Mease, Dafna D Gladman, Sandra Navarra, Weibin Bao, and Corine Gaillez

Link

Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension., Lihi Eder, Dafna D Gladman, Philip Mease, Remy A Pollock, Rayana Luna, Sibel Z Aydin, Alexis Ogdie, Ari Polachek, David Gruben, Mary Jane Cadatal, Cassandra Kinch, and Vibeke Strand

Link

Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis., Lihi Eder, Sivakami Mylvaganam, Jordi Pardo Pardo, Jennifer Petkovic, Vibeke Strand, Philip Mease, and Keith Colaco

Link

Continuity of Care Within a Single Patient Support Program for Patients with Rheumatoid Arthritis Prescribed Second or Later Line Advanced Therapy., A Mark Fendrick, Philip Mease, Matthew Davis, Pankaj Patel, Wes Matthias, Dominic Nunag, and Manish Mittal

Link

Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis., Alice B Gottlieb, Iain B McInnes, Proton Rahman, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty, Frederic Lavie, and Philip J Mease

Link

Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group., Ying-Ying Leung, William Tillett, Maarten de Wit, Ana-Maria Orbai, Laura C Coates, Oliver FitzGerald, Philip S Helliwell, Vibeke Strand, Philip Mease, Niti Goel, Robin Christensen, Joseph F Merola, Christine A Lindsay, Alexis Ogdie, Laure Gossec, and Dafna D Gladman

Link

Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies., Dennis McGonagle, Iain B McInnes, Atul Deodhar, Georg Schett, May Shawi, Soumya D Chakravarty, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Stephen Xu, Christopher T Ritchlin, Proton Rahman, and Phillip J Mease

Link

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)., Iain B McInnes, Akihiko Asahina, Laura C Coates, Robert Landewé, Joseph F Merola, Christopher T Ritchlin, Yoshiya Tanaka, Laure Gossec, Alice B Gottlieb, Richard B Warren, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, and Philip Mease

Link

Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study., Philip Mease, Dafna D Gladman, Denis Poddubnyy, Soumya D Chakravarty, May Shawi, Alexa P Kollmeier, Xie L Xu, Stephen Xu, Atul Deodhar, and Xenofon Baraliakos

Link

Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment., Philip Mease, Alice B Gottlieb, Alexis Ogdie, Iain B McInnes, Soumya D Chakravarty, Emmanouil Rampakakis, Alexa Kollmeier, Xie L Xu, May Shawi, Frederic Lavie, Mitsumasa Kishimoto, and Proton Rahman

Link

Efficacy and Safety of Tyrosine Kinase 2/Janus Kinase 1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial., Philip Mease, Philip Helliwell, Paula Silwinska-Stanczyk, Malgorzata Miakisz, Andrew Ostor, Elena Peeva, Michael S Vincent, Qiankun Sun, Vanja Sikirica, Randall Winnette, Ruolun Qiu, Gang Li, Gang Feng, Jean S Beebe, and David A Martin

Link

Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet's Syndrome., Philip J Mease, Gülen Hatemi, Maria Paris, Sue Cheng, Peter Maes, Wendy Zhang, Rebecca Shi, Andrea Flower, Hernan Picard, and Linda Stein Gold

Link

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry., Philip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Iris Lin, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, and Joseph F Merola

Link

Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies., Philip J Mease, Ana-Maria Orbai, Oliver FitzGerald, Mohamed Bedaiwi, Dona L Fleishaker, Rajiv Mundayat, Pamela Young, and Philip S Helliwell

Link

Impact of COVID-19 on Patients With Psoriasis or Psoriatic Arthritis., Philip Mease, Peter Nash, Suzanne Grieb, and Vinod Chandran

Link

Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study., Philip Mease, Arathi Setty, Kim Papp, Filip Van den Bosch, Shigeyoshi Tsuji, Mauro Keiserman, Kyle Carter, Yihan Li, Reva McCaskill, Erin McDearmon-Blondell, Peter Wung, and William Tillett

Link

Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study., Philip Mease, Arathi Setty, Kim Papp, Filip Van den Bosch, Shigeyoshi Tsuji, Mauro Keiserman, Kyle Carter, Yihan Li, Reva McCaskill, Erin McDearmon-Blondell, Peter Wung, and William Tillett

Link

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)., Joseph F Merola, Robert Landewé, Iain B McInnes, Philip Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Alice B Gottlieb, Diamant Thaçi, Richard B Warren, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, and Laura C Coates

Link

Physical Therapist Management of Glenohumeral Joint Osteoarthritis: A Clinical Practice Guideline from the American Physical Therapy Association., Lori A Michener, Jill Heitzman, Laurel D Abbruzzese, Salvador L Bondoc, Kristin Bowne, Phillip Troy Henning, Heidi Kosakowski, Brian G Leggin, Ann M Lucado, and Amee L Seitz

Link

Proceedings of the GRAPPA 2022 Executive Retreat., Beverly Cheok Kuan Ng, Deepak Jadon, Adewale Adebajo, Gizem Ayan, Kristina Callis Duffin, Vinod Chandran, Laura C Coates, Maria Antonietta D'Agostino, Kurt de Vlam, Atul Deodhar, Lihi Eder, Amit Garg, Dafna D Gladman, Niti Goel, Alice B Gottlieb, M Elaine Husni, Arnon Katz, Arthur Kavanaugh, Ennio Lubrano, Philip Mease, Joseph F Merola, Peter Nash, Alexis Ogdie, Stephen R Pennington, Lourdes M Perez-Chada, Fabian Proft, Cheryl F Rosen, Laura Savage, Claudia Goldenstein-Schainberg, Stefan Siebert, Enrique R Soriano, Ingrid Steinkoenig, William Tillett, April W Armstrong, and Oliver FitzGerald

Link

Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting., Beverly Cheok Kuan Ng, Deepak Jadon, Frank Behrens, Maarten de Wit, Oliver FitzGerald, Dafna D Gladman, Philip Mease, Denis O'Sullivan, Stephen R Pennington, Georg Schett, Vinod Chandran, and Kurt de Vlam

Link

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis., Alexis Ogdie, Dafna D Gladman, Laura C Coates, Effie Pournara, Bhumik Parikh, and Philip Mease

Link

Emotion regulation and the salience network: a hypothetical integrative model of fibromyalgia., Ana Margarida Pinto, Rinie Geenen, Tor D Wager, Mark A Lumley, Winfried Häuser, Eva Kosek, Jacob N Ablin, Kirstine Amris, Jaime Branco, Dan Buskila, João Castelhano, Miguel Castelo-Branco, Leslie J Crofford, Mary-Ann Fitzcharles, Marina López-Solà, Mariana Luís, Tiago Reis Marques, Philip J Mease, Filipe Palavra, Jamie L Rhudy, Lucina Q Uddin, Paula Castilho, Johannes W G Jacobs, and José A P da Silva

Link

Reply to 'Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?'., Ana Margarida Pinto, Rinie Geenen, Tor D Wager, Mark A Lumley, Winfried Häuser, Eva Kosek, Jacob N Ablin, Kirstine Amris, Jaime Branco, Dan Buskila, João Castelhano, Miguel Castelo-Branco, Leslie J Crofford, Mary-Ann Fitzcharles, Marina López-Solà, Mariana Luís, Tiago Reis Marques, Philip Mease, Filipe Palavra, Jamie L Rhudy, Lucina Q Uddin, Paula Castilho, Johannes W G Jacobs, and José A P da Silva

Link

Neurophysiological and psychosocial mechanisms of fibromyalgia: A comprehensive review and call for an integrative model., Ana Margarida Pinto, Mariana Luís, Rinie Geenen, Filipe Palavra, Mark A Lumley, Jacob N Ablin, Kirstine Amris, Jaime Branco, Dan Buskila, João Castelhano, Miguel Castelo-Branco, Leslie J Crofford, Mary-Ann Fitzcharles, Winfried Häuser, Eva Kosek, Philip J Mease, Tiago Reis Marques, Johannes W G Jacobs, Paula Castilho, and José A P da Silva

Link

Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis., Proton Rahman, Wolf-Henning Boehncke, Philip J Mease, Alice B Gottlieb, Iain B McInnes, May Shawi, Yanli Wang, Shihong Sheng, Alexa P Kollmeier, Elke Theander, Jenny Yu, Evan Leibowitz, A Marilise Marrache, and Laura C Coates

Link

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study., Christopher T Ritchlin, Laura C Coates, Iain B McInnes, Philip Mease, Joseph F Merola, Yoshiya Tanaka, Akihiko Asahina, Laure Gossec, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, and Robert Bm Landewé

Link

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial., Christopher T Ritchlin, Laura C Coates, Philip J Mease, Désirée van der Heijde, Jiao Song, Yusang Jiang, May Shawi, Alexa P Kollmeier, and Proton Rahman

Link

Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies., Emilce E Schneeberger, Gustavo Citera, Peter Nash, Josef S Smolen, Philip Mease, Enrique R Soriano, Claudia Helling, Annette E Szumski, Rajiv Mundayat, and Darío Ponce de León

Link

Project Highlights From the GRAPPA 2022 Annual Meeting: Education Initiatives and Axial Involvement in Psoriatic Arthritis., Murat Torgutalp, Dafna D Gladman, Oliver FitzGerald, Philip Mease, and Denis Poddubnyy

Link

Similarities and differences between axial spondyloarthritis and axial psoriatic arthritis., Weijie Wang, Yung-Heng Lee, James Cheng-Chung Wei, and Philip Mease

Link

Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022., Kevin L Winthrop, John D Isaacs, Philip J Mease, Dimitrios T Boumpas, Xenofon Baraliakos, Jacques-Eric Gottenberg, Stefan Siebert, Marta Mosca, Neil Basu, Dana Orange, R Lories, Daniel Aletaha, Iain B McInnes, Tom W J Huizinga, Reinhard E Voll, Ellen M Gravallese, Ferry C Breedveld, and Josef S Smolen

Submissions from 2022

Link

Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group., Anna Antony, Richard Holland, Ashish J Mathew, Maria-Antoinetta D'Agostino, Walter P Maksymowych, Philip Mease, Niti Goel, Alexis Ogdie, Laura C Coates, Vibeke Strand, Robin Christensen, Dafna D Gladman, Ana-Maria Orbai, Ying Ying Leung, and William Tillett

Link

2021 GRAPPA Meet the Experts Session: A Summary of Presentations., April W Armstrong, Rasika M Reddy, Oliver FitzGerald, Kristina Callis Duffin, Philip S Helliwell, Philip Mease, Arthur Kavanaugh, Joseph F Merola, William Tillet, and Maarten de Wit

Link

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial., Xenofon Baraliakos, Effie Pournara, Laure Gossec, Philip J Mease, Roisin White, Eamonn O'Brien, Barbara Schulz, Helena Marzo-Ortega, and Laura C Coates

Link

Novel therapies in axial spondyloarthritis., Mohamad Bittar and Philip Mease

Link

Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results., Laura C Coates, Philip Mease, Andris Kronbergs, Cameron Helt, David Sandoval, So Young Park, Bernard Combe, Peter Nash, and Atul Deodhar

Link

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results., Laura C Coates, Philip Mease, Andris Kronbergs, Cameron Helt, David Sandoval, So Young Park, Bernard Combe, Peter Nash, and Atul Deodhar

Link

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis., Laura C Coates, Christopher T Ritchlin, Laure Gossec, Philip S Helliwell, Proton Rahman, Alexa P Kollmeier, Xie L Xu, May Shawi, Chetan S Karyekar, Christine Contré, Wim Noël, Shihong Sheng, Yanli Wang, Stephen Xu, and Philip Mease

Link

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis., Laura C Coates, Josef S Smolen, Philip Mease, M Elaine Husni, Joseph F Merola, Eric Lespessailles, Mitsumasa Kishimoto, Lisa Macpherson, Andrew J Bradley, Rebecca Bolce, and Philip S Helliwell

Link

Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021., Laura C Coates, Enrique R Soriano, Nadia Corp, Heidi Bertheussen, Kristina Callis Duffin, Cristiano B Campanholo, Jeffrey Chau, Lihi Eder, Daniel G Fernández-Ávila, Oliver FitzGerald, Amit Garg, Dafna D Gladman, Niti Goel, Philip S Helliwell, M Elaine Husni, Deepak R Jadon, Arnon Katz, Dhruvkumar Laheru, John Latella, Ying-Ying Leung, Christine Lindsay, Ennio Lubrano, Luis Daniel Mazzuoccolo, Philip J Mease, Denis O'Sullivan, Alexis Ogdie, Wendy Olsder, Penelope Esther Palominos, Lori Schick, Ingrid Steinkoenig, Maarten de Wit, D A van der Windt, Arthur Kavanaugh, and GRAPPA Treatment Recommendations domain subcommittees

Link

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021., Laura C Coates, Enrique R Soriano, Nadia Corp, Heidi Bertheussen, Kristina Callis Duffin, Cristiano B Campanholo, Jeffrey Chau, Lihi Eder, Daniel G Fernández-Ávila, Oliver FitzGerald, Amit Garg, Dafna D Gladman, Niti Goel, Philip S Helliwell, M Elaine Husni, Deepak R Jadon, Arnon Katz, Dhruvkumar Laheru, John Latella, Ying-Ying Leung, Christine Lindsay, Ennio Lubrano, Luis Daniel Mazzuoccolo, Philip Mease, Denis O'Sullivan, Alexis Ogdie, Wendy Olsder, Penelope Esther Palominos, Lori Schick, Ingrid Steinkoenig, Maarten de Wit, D A van der Windt, and Arthur Kavanaugh

Link

The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial., Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Steven Peterson, Prasheen Agarwal, Feifei Yang, Alexa P Kollmeier, Elizabeth C Hsia, Natalie J Shiff, Bei Zhou, Chenglong Han, May Shawi, William Tillett, and Philip Mease

Link

The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial., Jeffrey R Curtis, Iain B McInnes, Proton Rahman, Dafna D Gladman, Feifei Yang, Steven Peterson, Prasheen Agarwal, Alexa P Kollmeier, Elizabeth C Hsia, Chenglong Han, Natalie J Shiff, May Shawi, William Tillett, and Philip Mease

Link

Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis., Kurt de Vlam, Philip Mease, Andrew G Bushmakin, Roy Fleischmann, Alexis Ogdie, Valderilio F Azevedo, Joseph F Merola, John Woolcott, Joseph C Cappelleri, Lara Fallon, and Peter C Taylor

Link

Management of Enthesitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations., Lihi Eder, Ashish J Mathew, Philippe Carron, Heidi Bertheussen, Juan D Cañete, May Azem, Andrea Delle Sedie, Carlo Salvarani, Roberto Ranza, Ashley Elliott, Anthony Turkiewicz, Ricardo Acayaba de Toledo, Hulya Bukulmez, Maria S Stoenoiu, Arthur M Mandelin, Michaela Koehm, Chris Lindsay, Evan Siegel, and Philip Mease

Link

Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landewé., Dafna D Gladman, Philip Mease, Paul Bird, Enrique R Soriano, Soumya D Chakravarty, May Shawi, Frederic Lavie, Cinty Gong, Evan Leibowitz, Denis Poddubnyy, Lai-Shan Tam, Philip S Helliwell, Arthur Kavanaugh, Atul A Deodhar, Mikkel Østergaard, and Xenofon Baraliakos

Link

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial., Dafna D Gladman, Philip Mease, Paul Bird, Enrique R Soriano, Soumya D Chakravarty, May Shawi, Stephen Xu, Sean T Quinn, Cinty Gong, Evan Leibowitz, Denis Poddubnyy, Lai-Shan Tam, Philip S Helliwell, Arthur Kavanaugh, Atul Deodhar, Mikkel Østergaard, and Xenofon Baraliakos

Link

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data., Alice B Gottlieb, Atul Deodhar, Iain B Mcinnes, Xenofon Baraliakos, Kristian Reich, Stefan Schreiber, Weibin Bao, Kwaku Marfo, Hanno B Richards, Luminita Pricop, Abhijit Shete, Vivek Trivedi, Deborah Keefe, Charis C Papavassilis, Piotr Jagiello, Philemon Papanastasiou, Philip Mease, and Mark Lebwohl

Link

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial., Philip S Helliwell, Philip Mease, Arthur Kavanaugh, Laura C Coates, Alexis Ogdie, Atul Deodhar, Vibeke Strand, Gregory Kricorian, Lyrica X H Liu, David Collier, and Dafna D Gladman

Link

Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study., Bruce Kirkham, Peter Nash, Delia Reina, Sandra Navarra, Erhard Quebe-Fehling, Corine Gaillez, Carlos Sastre, and Philip Mease

Link

Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials., Iain B McInnes, Andrew J K Ostor, Philip Mease, William Tillett, Xenofon Baraliakos, Kurt de Vlam, Louis Bessette, Ralph Lippe, Anna Maniccia, Dai Feng, Tianming Gao, Patrick Zueger, Christopher Saffore, Koji Kato, In-Ho Song, and Atul Deodhar

Link

Suspecting and Diagnosing the Patient with Spondyloarthritis and What to Expect from Therapy., Philip Mease

Link

Effectiveness of 6-Month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Taylor Blachley, Blessing Dube, Robert R McLean, Nina Kim, Peter Hur, and Alexis Ogdie

Link

Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen-B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Soumya D Chakravarty, Robert R McLean, Taylor Blachley, Toana Kawashima, Iris Lin, Arthur Kavanaugh, and Alexis Ogdie

Link

Differentiating nonradiographic axial spondyloarthritis from its mimics: a narrative review., Philip Mease and Atul Deodhar

Link

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis., Philip Mease, Atul A Deodhar, Désirée van der Heijde, Frank Behrens, Alan J Kivitz, Jeffrey Neal, Jonghyeon Kim, Shalabh Singhal, Miroslawa Nowak, and Subhashis Banerjee

Link

Potential Impact of Sex and Body Mass Index on Response to Therapy in Psoriatic Arthritis: Post-hoc Analysis of Results From the SEAM-PsA Trial., Philip Mease, Dafna D Gladman, Joseph F Merola, Atul Deodhar, Alexis Ogdie, David H Collier, Lyrica Liu, and Arthur Kavanaugh

Link

Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE., Philip J Mease, Akihiko Asahina, Dafna D Gladman, Yoshiya Tanaka, William Tillett, Barbara Ink, Deepak Assudani, Christine de la Loge, Jason Coarse, Jason Eells, and Laure Gossec

Link

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry., Philip J Mease, Alexis Ogdie, Soumya D Chakravarty, Natalie J Shiff, Iris Lin, Robert R McLean, Wendi Malley, Rebecca L Spitzer, Arthur Kavanaugh, and Joseph F Merola

Link

Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials., Philip Mease, Arthur Kavanaugh, Dafna Gladman, Oliver FitzGerald, Enrique R Soriano, Peter Nash, Dai Feng, Apinya Lertratanakul, Kevin Douglas, Ralph Lippe, and Laure Gossec

Link

Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase 3 Results in DMARD-Naive Patients With Psoriatic Arthritis., Philip Mease, Arthur Kavanaugh, Alexis Ogdie, Alvin F Wells, Martin Bergman, Dafna D Gladman, Sven Richter, Lichen Teng, Shauna Jardon, and Josef S Smolen

Link

Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial., Philip Mease, Herbert Kellner, Akimichi Morita, Alan J Kivitz, Stella Aslanyan, Steven J Padula, Andrew S Topp, Ann Eldred, Frank Behrens, and Kim A Papp

Link

Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Updates to a Systematic Literature Review and Network Meta-Analysis., Philip Mease, Iain B McInnes, Lai-Shan Tam, Raji Rajalingam, Steve Peterson, Fareen Hassan, Soumya D Chakravarty, Christine Contré, Alison Armstrong, Wolf-Henning Boehncke, and Christopher Ritchlin

Link

Best practice and research advances in many aspects of rheumatology., Philip Mease and Janet Pope

Link

Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis., Philip Mease, Désirée van der Heijde, Bruce Kirkham, Georg Schett, Ana-Maria Orbai, Christopher Ritchlin, Joseph F Merola, Luminita Pricop, David A James, Xuan Zhu, and Gregory Ligozio

Link

COVID-19 Update for the GRAPPA 2021 Annual Meeting: Focus on COVID-19 Vaccination., Philip Mease, Kevin Winthrop, Wendy Olsder, and Jeffrey R Curtis

Link

Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database., Philip Mease, Pamela Young, David Gruben, Lara Fallon, Rebecca Germino, and Arthur Kavanaugh

Link

Instrument selection for the ASAS core outcome set for axial spondyloarthritis., Victoria Navarro-Compán, Anne Boel, Annelies Boonen, Philip Mease, Maxime Dougados, Uta Kiltz, Robert B M Landewé, Xenofon Baraliakos, Wilson Bautista-Molano, Praveena Chiowchanwisawakit, Hanne Dagfinrud, Lara Fallon, Marco Garrido-Cumbrera, Lianne Gensler, Bassel Kamal ElZorkany, Nigil Haroon, Yu Heng Kwan, Pedro M Machado, Walter Maksymowych, Anna Molto, Natasha de Peyrecave, Denis Poddubnyy, Mikhail Protopopov, Sofia Ramiro, In-Ho Song, Salima van Weely, and Désirée van der Heijde

Link

Prospective Cohort Study of Psoriatic Arthritis Risk in Patients With Psoriasis in a Real-World Psoriasis Registry., Alexis Ogdie, Ryan W Harrison, Robert R McLean, Tin-Chi Lin, Mark Lebwohl, Bruce E Strober, Joe Zhuo, Vardhaman Patel, and Philip J Mease

Link

Challenges in the Diagnosis and Assessment of Psoriatic Arthritis., Alexis Ogdie, Christine A Lindsay, Philip Mease, Kristina Callis Duffin, Cheryl F Rosen, and Stefan Siebert

Link

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies., Ana-Maria Orbai, Philip J Mease, Philip S Helliwell, Oliver FitzGerald, Dona L Fleishaker, Rajiv Mundayat, and Pamela Young

Link

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies., Christopher T Ritchlin, Philip Mease, Wolf-Henning Boehncke, John Tesser, Elena Schiopu, Soumya D Chakravarty, Alexa P Kollmeier, Xie L Xu, May Shawi, Yusang Jiang, Shihong Sheng, Yanli Wang, Stephen Xu, Joseph F Merola, Iain B McInnes, and Atul Deodhar

Link

Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases., Stefan Schreiber, Luis Puig, João Gonçalves, Philip Mease, Remo Panaccione, and Paul Emery

Link

Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting., Carmel Stober, Iain B McInnes, Soumya Raychaudhuri, Philip Mease, Stephen R Pennington, Jose U Scher, Vinod Chandran, April W Armstrong, Maarten de Wit, Alberto Cauli, Deepak R Jadon, Thorvardur J Löve, Alexis Ogdie, Denis O'Sullivan, Leonieke J J van Mens, Christopher T Ritchlin, and Oliver FitzGerald

Link

Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis., William Tillett, Laura C Coates, Sandeep Kiri, Vanessa Taieb, Damon Willems, and Philip Mease

Link

Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects., James C Waddington, Orla Coleman, Philip Mease, Vinod Chandran, Denis O'Sullivan, Oliver FitzGerald, and Stephen R Pennington

Submissions from 2021

Link

Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative., Anna Antony, Richard Holland, Maria-Antonietta D'Agostino, Walter P Maksymowych, Heidi Bertheussen, Lori Schick, Niti Goel, Alexis Ogdie, Ana-Maria Orbai, P Højgaard, Laura C Coates, Vibeke Strand, Dafna D Gladman, Robin Christensen, Ying Ying Leung, Philip Mease, and William Tillett